Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market

Photo Credit: © Bert Folsom / Adobe Stock — used under Standard Editorial License.

The following is a 250-word excerpt from my full article on Seeking Alpha: A crowdsourced financial market content service where investors can share ideas, discuss news, and make informed investment decisions. Below is a link to the full article:
https://seekingalpha.com/article/4857281-niagen-bioscience-why-discipline-matters-in-a-crowded-supplement-market

Summary

• Niagen Bioscience continues to see improving demand for Tru Niagen, strengthening cash generation, and a debt-free balance sheet, supporting a more positive but still balanced investment outlook.

• Niagen Bioscience's near-term valuation remains constrained by historical dilution and normalized gross margins expected in the low 60% range.

• Niagen Bioscience is prioritizing conservative capital allocation, including disciplined reinvestment and a modest share repurchase program, limiting downside risk.

• Niagen Bioscience's longer-term upside is tied to Niagen Plus and potential at-home injectable delivery, though these initiatives remain early and carry execution and regulatory risk.

Investment Thesis

I reaffirm my hold rating on Niagen Bioscience (NAGE), though it is a much more positive hold rating than from my prior articles, albeit still short of a buy rating. Demand for the company's main product, Tru Niagen, is growing, cash generation is further improving, and the balance sheet remains debt-free with meaningful liquidity on hand. And the company's recent momentum is being driven by brand trust and organic consumer pull as opposed to aggressive marketing. Nevertheless, the company still has their historical dilution overhang (though it is worth noting that the company doesn't need to raise capital anymore, thus eliminating the potential for future dilution), and normalized gross margins are likely to remain in the low 60% range—two factors that I believe still limit the stock's near-term valuation appeal. Still, there is much longer-term upside ahead through Niagen Plus and an eventual at-home injectable model, though these initiatives, as much as I like them and as innovative as they are, are still early and carry both execution and regulatory risk…